Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Danielle Brazel,1 Shannon Zhang,1 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3Department of Medicine, St. Marianna University School of Medicine, Kawasaki, JapanCorrespon...

Full description

Bibliographic Details
Main Authors: Brazel D, Zhang S, Nagasaka M
Format: Article
Language:English
Published: Dove Medical Press 2022-05-01
Series:Lung Cancer: Targets and Therapy
Subjects:
tepotinib
capmatinib
mesenchymal-epithelial transition inhibitors
met
ret
non-small cell lung cancer
Online Access:https://www.dovepress.com/spotlight-on-tepotinib-and-capmatinib-for-non-small-cell-lung-cancer-w-peer-reviewed-fulltext-article-LCTT

Internet

https://www.dovepress.com/spotlight-on-tepotinib-and-capmatinib-for-non-small-cell-lung-cancer-w-peer-reviewed-fulltext-article-LCTT

Similar Items